

23 July 2013

2013/14 Invitation to Tender

PHARMAC is seeking feedback from medical groups, DHB hospital pharmacies and other interested parties on:

- A proposal to tender certain pharmaceuticals for sole supply; and
- The draft process and terms and conditions for the 2013/14 Invitation to Tender (2013/14 Tender).

PHARMAC welcomes all feedback on the 2013/14 Tender. Feedback received by the deadline may be considered by the Tender Medical Evaluation Subcommittee of PTAC, and would be considered by the PHARMAC Board (or its Delegate) prior to making a decision on this proposal.

ALL RESPONSES ARE DUE BY 5PM, THURSDAY 5 SEPTEMBER 2013

Feedback should be provided by submitting an email, fax or letter to:

Chloe Dimock
Tender Analyst
PHARMAC
PO Box 10-254
Wellington 6143

Email: chloe.dimock@pharmac.govt.nz

Fax: (04) 460 4995
DDI: (04) 916 7263

Feedback we receive is subject to the Official Information Act 1982 (OIA) and we will consider any request to have information withheld in accordance with our obligations under the OIA. Anyone providing feedback, whether on their own account or on behalf of an organisation, and whether in a personal or professional capacity, should be aware that the content of their feedback and their identity may need to be disclosed in response to an OIA request.

We are not able to treat any part of your feedback as confidential unless you specifically request that we do, and then only to the extent permissible under the OIA and other relevant laws and requirements. If you would like us to withhold any commercially sensitive, confidential proprietary, or personal information included in your submission, please clearly state this in your submission and identify the relevant sections of your submission that you would like it withheld. PHARMAC will give due consideration to any such request.

Details of the proposed 2013/14 Tender

In accordance with PHARMAC's objective (to secure, for eligible people in need of pharmaceuticals, the best health outcomes that are reasonably achievable from pharmaceutical treatment and from within the amount of funding provided), PHARMAC is consulting on a proposal to tender certain pharmaceuticals for Sole Subsidised Supply to

community pharmacies and/or Hospital Supply Status for supply to DHB hospital pharmacies.

Attached to this letter (as Schedule One) is a list of pharmaceuticals that we are considering tendering for Sole Subsidised Supply and/or Hospital Supply Status. Pharmaceuticals are sorted into therapeutic groups and then listed alphabetically in each group by chemical, form and strength. Each pharmaceutical has a 'C' and/or 'H' next to it to indicate whether it is proposed to be tendered for community and/or hospital supply.

In general, the proposed Tender process would be similar to the 2012/13 Tender. A copy of the draft 2013/14 Invitation to Tender is available on our website: www.pharmac.health.nz, or by contacting PHARMAC.

We are seeking feedback on the approach outlined in the following pages, in particular on:

- The proposed tender process and timeline;
- The actual or potential clinical implications of awarding Sole Subsidised Supply and/or Hospital Supply Status to the pharmaceuticals listed in Schedule One, including the impact of a brand switch on patients and clinical staff; and
- For hospital pharmaceuticals, your views on the appropriate Discretionary Variance (DV) Limit for each pharmaceutical, in the event you consider a 1% DV Limit to be clinically unacceptable.

Background

Since 1997 PHARMAC has been using the strategy of tendering pharmaceuticals for sole supply of pharmaceuticals for a fixed period of time. Regular tendering has proven to be an effective way to encourage competition among suppliers of pharmaceuticals. As in the past, the community and hospital tender processes would be run in unison, however, the pharmaceutical list for community and hospital supply may be different.

Key Aspects of Awarding a Tender for Community Pharmaceuticals:

- For community pharmaceuticals, the tender winning brand would be the only subsidised brand for up to approximately 3 years. The Sole Subsidised Supply period would conclude on 30 June 2017 for all Tenders awarded from the 2013/14 Tender.
- No other brand of the pharmaceutical would be listed (or subsidised) in Section B of the Pharmaceutical Schedule during the Sole Subsidised Supply period.
- Other brands could continue to be marketed, sold and dispensed during the Sole Subsidised Supply Status period, but they would not receive a subsidy.
- Any pharmaceutical that currently carries a manufacturer's surcharge (that is, the additional patient charge above that of the patient co-payment) would become fully subsidised if a tender was awarded for that pharmaceutical.

Key Aspects of Awarding a Tender for DHB Hospital Pharmaceuticals:

- For DHB hospital pharmaceuticals, the Hospital Supply Status brand would be the only brand DHB Hospitals could purchase (subject to any allowance for alternative

brands under the agreed DV Limits) for up to approximately 3 years. The Hospital Supply Status period would conclude on 30 June 2017 for all tenders awarded from the 2013/14 Tender.

- No other brand of the pharmaceutical would be listed in Section H of the Pharmaceutical Schedule during the Hospital Supply Status period.

Tender Timelines

The proposed timelines for the 2013/14 Tender are as follows:

Date	Event
23 July 2013	Consultation with suppliers, medical groups and interested parties on the proposed pharmaceutical list and draft Invitation to Tender.
22 August 2013	Final date for receipt of Alternative Commercial Proposals (ACPs) to tendering by PHARMAC.
5 September 2013	Final date for all consultation to be received.
September 2013	PHARMAC considers feedback from consultation, negotiates with suppliers over any ACP proposals it considers would meet PHARMAC's Decision Criteria and enters into provisional contracts with suppliers where appropriate.
September 2013	Meeting of the Tender Medical Evaluation Subcommittee of PTAC to consider clinical issues in relation to the proposed Tender list.
September/October 2013	Consultation and Board decisions on Alternative Commercial Proposals.
Early November 2013	Issuing of the 2012/13 Tender.
19 December 2013	Invitation to Tender closes.
From end of January 2014	Board decisions on the first Tender winners announced.

Contractual obligations for suppliers

A copy of the draft terms and conditions which would form the terms of the 2013/14 Tender contract is available on the PHARMAC website: www.pharmac.health.nz, or by phoning PHARMAC on 0800 66 00 50.

Unresolved Tender Bids

PHARMAC would review any unresolved Tender Bids from 2011/12 Tender and the 2012/13 Tender prior to issuing the 2013/14 Tender, and may close the tender for some of these items, and reissue them as part of the 2013/14 tender. The following Tender Bids remain unresolved, and may potentially be added to the 2013/14 Tender following consultation:

2011/12 Invitation to Tender

Chemical Name	Line Item
Amoxicillin	Grans for oral liq 125 mg per 5 ml
Amoxicillin	Grans for oral liq 250 mg per 5 ml
Brinzolamide	Eye Drops 1%

Chemical Name	Line Item
Bupivacaine Hydrochloride	Inj 0.5%, 10 ml
Clonidine	TDDS 2.5 mg, 100 mcg per day
Clonidine	TDDS 5 mg, 200 mcg per day
Clonidine	TDDS 7.5 mg, 300 mcg per day
Granisetron	Inj 1 mg
Granisetron	Tab 1 mg
Intra-Uterine Device	IUD - Short length (5 - 8 cm)
Intra-Uterine Device	IUD - Standard length (6 - 9 cm)
Lignocaine Hydrochloride	Inj 1%, 2 ml
Lignocaine Hydrochloride	Inj 2%, 2 ml
Methotrexate	Tab 2.5 mg
Methotrexate	Tab 10 mg
Morphine Sulphate	Tab immediate release 10 mg
Morphine Sulphate	Tab immediate release 20 mg
Oxycodone Hydrochloride	Cap 5 mg
Oxycodone Hydrochloride	Cap 10 mg
Oxycodone Hydrochloride	Cap 20 mg
Oxycodone Hydrochloride	Tab controlled-release 5 mg
Oxytocin	Inj 5 iu per ml, 1 ml
Oxytocin	Inj 10 iu per ml, 1 ml
Travoprost	Eye drops 0.004%
Tropisetron	Inj 1 mg per ml, 5 ml
Tropisetron	Inj 1 mg per ml, 2 ml

2012/13 Invitation to Tender

Chemical Name	Line Item
Aripiprazole	Tab 20 mg
Aripiprazole	Tab 30 mg
Aripiprazole	Tab 15 mg
Aripiprazole	Tab 10 mg
Azathioprine	Inj 50 mg
Azathioprine	Tab 25 mg
Azathioprine	Tab 50 mg
Beclomethasone Dipropionate	Metered aqueous nasal spray, 50 mcg per dose
Beclomethasone Dipropionate	Metered aqueous nasal spray, 100 mcg per dose
Betamethasone Valerate	Lotn 0.1%
Betamethasone Valerate	Crn 0.1%
Bisacodyl	Tab 5 mg
Budesonide	Metered aqueous nasal spray, 100 mcg per dose
Budesonide	Metered aqueous nasal spray, 50 mcg per dose

Chemical Name	Line Item
Capecitabine	Tab 500 mg
Capecitabine	Tab 150 mg
Ceftriaxone Sodium	Inf 2 g
Ceftriaxone Sodium	Inj 1 g
Ceftriaxone Sodium	Inj 500 mg
Cetomacrogol	Crn BP
Cholecalciferol	Tab 1.25 mg (50,000 iu)
Ciprofloxacin	Inj 2 mg per ml, 100 ml
Clobetasol Propionate	Crn 0.05% (pack size 30 g or less)
Clobetasol Propionate	Oint 0.05% (pack size 30 g or less)
Coal Tar	Soln BP
Co-Trimoxazole	Tab trimethoprim 80 mg and sulphamethoxazole 400 mg
Dexamethasone phosphate	Inj 4 mg per ml, 2 ml
Dexamethasone phosphate	Inj 4 mg per ml, 1 ml

Chemical Name	Line Item
Dextrose with Electrolytes	Soln with electrolytes
Dimethicone	Crn 5%
Dimethicone	Crn 5%
Docusate Sodium with Sennosides	Tab 50 mg with total sennosides 8 mg
Dorzolamide hydrochloride with timolol maleate	Eye drops 2% with timolol maleate 0.5%
Escitalopram	Tab 10 mg
Escitalopram	Tab 20 mg
Ferrous Salts	Oral liq
Flecainide Acetate	Cap long-acting 100 mg
Flecainide Acetate	Tab 50 mg
Flecainide Acetate	Cap long-acting 200 mg
Flecainide Acetate	Tab 100 mg
Fluoxetine Hydrochloride	Cap 20 mg
Fluoxetine Hydrochloride	Tab dispersible 20 mg, scored
Fusidic Acid	Crn 2 %
Glycopyrronium with neostigmine	Inj 500 mcg with 2.5 mg neostigmine per ml, 1 ml
Hydrocortisone with Miconazole	Crn 1% with miconazole nitrate 2%
Ibuprofen	Oral liq 100 mg per 5 ml
Iloprost	Inj 100 µg per ml, 0.5 ml
Latanoprost with timolol	Eye drops 50 mcg per ml with timolol 0.5%
Loperamide Hydrochloride	Cap 2 mg
Loratadine	Oral liq 1 mg per ml
Lorazepam	Tab 1 mg
Lorazepam	Tab 2.5 mg
Magnesium	Tab
Methadone Hydrochloride	Tab 5 mg
Minocycline Hydrochloride	Tab 50 mg
Mitozantrone	Inj 2 mg per ml, 12.5 ml
Mupirocin	Oint 2%
Nystatin	Cap 500,000 u
Nystatin	Tab 500,000 u
Oestradiol	TDDS 100 mcg per day
Oestradiol	TDDS 75 mcg per day
Oestradiol	TDDS 50 mcg per day
Oestradiol	TDDS 25 mcg per day
Olanzapine	Tab 2.5 mg
Olanzapine	Tab 10 mg
Olanzapine	Tab 5 mg
Olanzapine	Orodispersible tab 10 mg
Olanzapine	Orodispersible tab 5 mg
Pantoprazole	Tab 20 mg

Chemical Name	Line Item
Pantoprazole	Tab 40 mg
Paroxetine Hydrochloride	Tab 20 mg
Pegylated liposomal doxorubicin	Inj 20 mg
Pegylated liposomal doxorubicin	Inj 50 mg
Phenoxymethylpenicillin (Penicillin V)	Grans for oral liq 250 mg per 5 ml
Phenoxymethylpenicillin (Penicillin V)	Cap 250 mg
Phenoxymethylpenicillin (Penicillin V)	Cap 500 mg
Phenoxymethylpenicillin (Penicillin V)	Grans for oral liq 125 mg per 5 ml
Pramipexole Hydrochloride	Tab 1 mg
Pramipexole Hydrochloride	Tab 0.250 mg
Pramipexole Hydrochloride	Tab 0.5 mg
Prednisolone	Oral liq 5 mg per ml
Quinine Sulphate	Tab 300 mg
Rosuvastatin	Tab 5 mg
Rosuvastatin	Tab 10 mg
Rosuvastatin	Tab 20 mg
Rosuvastatin	Tab 40 mg
Sodium chloride	Inj 0.9%, 20 ml
Sodium chloride	Inj 0.9%, 10 ml
Sodium chloride	Inj 0.9%, 5 ml
Sodium Citro-Tartrate	Grans effervescent 4 g sachets
Sodium Cromoglycate	Eye drops 2%
Solifenacin succinate	Tab 10 mg
Solifenacin succinate	Tab 5 mg
Tenoxicam	Inj 20 mg
Tenoxicam	Tab 20 mg
Thalidomide	Cap 100 mg
Thalidomide	Cap 50 mg
Tranexamic Acid	Tab 500 mg
Tranexamic Acid	Inj 100 mg per ml, 5 ml - 10 ml
Urea	Crn 10%
Valaciclovir	Tab 250 mg
Valaciclovir	Tab 1000 mg
Valaciclovir	Tab 500 mg
Water for Injection	Purified for inj 10 ml
Water for Injection	Purified for inj 5 ml
Water for Injection	Purified for inj 20 ml
Ziprasidone	Cap 40 mg
Ziprasidone	Cap 60 mg
Ziprasidone	Cap 20 mg
Ziprasidone	Cap 80 mg

Should any unresolved Tender Bids be declined, PHARMAC would consider including those pharmaceuticals in the 2013/14 Tender. Currently unresolved Tender Bids have not been included in the draft pharmaceutical list set out in Schedule One.

Distribution of Consultation Documents

Although this consultation letter has been widely distributed, should you consider that a particular person, group or agency should receive this letter and/or future tender documents, please feel free to contact PHARMAC or refer it on directly (note, all tender documents and consultations are also available from our website at www.pharmac.health.nz/news#consultation). We also invite any person or group to contact PHARMAC should you wish to meet to discuss the proposals contained in this consultation letter.

Schedule One: Possible pharmaceuticals for tender for sole supply

Order of pharmaceuticals in this Schedule

Pharmaceuticals have been listed in groups according to the therapeutic group classification system used in the Pharmaceutical Schedule. Below is a list of these groups, and the corresponding page numbers for your ease of reference. Pharmaceuticals with indications that may apply to multiple therapeutic groups will only appear in one group.

<i>Therapeutic Group</i>	Page Numbers
Alimentary Tract and Metabolism	8 – 9
Blood and Blood Forming Organs	9 –10
Cardiovascular System	10 – 13
Dermatologicals	13 – 14
Extemporaneously Compounded Preparations & Galenicals	14
Genito-Urinary System	14-15
Hormone Preparations – Systemic excluding contraceptives	15
Infections – Agents for Systemic Use	15– 20
Musculoskeletal System	20 – 22
Nervous System	22 –30
Oncology and Immunosuppressants	30 – 32
Respiratory System and Allergies	32 – 33
Sensory Organs	33-37

Information provided for each pharmaceutical

For each pharmaceutical (as defined by chemical name, form and strength) we have provided the following information:

- the current ex-manufacturer subsidy per unit of measure as at 1 July 2013
- the number of subsidised or partially subsidised units sold in the community in the year ending 30 June 2012
- an estimate of the annual community market value at current subsidies (estimated by multiplying the volume of units subsidised in the year ending 30 June 2012 by the relevant listed unit subsidy as at 1 July 2013); and

- comments specifically relating to the Tender of the line item and/or its current listing on the Pharmaceutical Schedule.

Explanation of terms, symbols and abbreviations

Most terms and abbreviations used are self explanatory: “tab” means tablet, “cap” means capsule, “liq” means liquid, “inj” means injection, “suppos” means suppository, “grans” mean granules and “OP” means original pack to be dispensed.

The following table explains the symbols used in the draft pharmaceutical list:

Symbol	Explanation
Underlined	Pharmaceutical line items where a sole supply contract is in force are underlined. The price and subsidy for these pharmaceuticals are fixed until 30 June 2013 unless otherwise stated in the Comments column and a listing of a new brand could only occur after that date.
C	To be tendered for Sole Subsidised Supply Status (community pharmaceuticals).
H	To be tendered for Hospital Supply Status (DHB hospital pharmaceuticals).
PCT	A reference in the Invitation to Tender to allow Pharmaceuticals Cancer Treatments to be listed in Section B of the Pharmaceutical Schedule as part of PHARMAC’s Pharmaceutical Cancer Treatments project.
+	PHARMAC has been advised of the existence of a patent.
*	There is no fully funded product available for this line item (in relation to community supply).
@	Additional Stock Pharmaceuticals (ASP) means a Pharmaceutical, marked with an “@”, for which the supplier of the successful Tender Bid would be required to hold additional stock.

SCHEDULE ONE: PHARMACEUTICALS TO BE TENDERED (DRAFT)

Chemical Name

Line Item

Units

Cost

Unit Subsidy

DV Limit

Comments

Alimentary Tract and Metabolism

Calcium carbonate

<u>Tab eff 0.875 - 1.75 g (0.5 g - 1 g elemental)</u>	1,154,970	\$239,079	\$0.2070	C H	1%
<u>Tab 1.25 g (500 mg elemental) - Tab 1.5 g (600 mg elemental)</u>	16,559,093	\$422,588	\$0.0255	C H	1%

Docusate Sodium

<u>Tab 50 mg</u>	560,121	\$14,395	\$0.0257	C H	1%
<u>Tab 120 mg</u>	1,593,207	\$55,444	\$0.0348	C H	1%

Esomeprazole

<u>Inj 40 mg</u>				C H	1%	Not currently listed in Section B of the Pharmaceutical Schedule
<u>Tab 20 mg</u>				C H	1%	Not currently listed in Section B of the Pharmaceutical Schedule
<u>Tab 40 mg</u>				C H	1%	Not currently listed in Section B of the Pharmaceutical Schedule

Gliclazide

<u>Tab 80 mg</u>	23,804,911	\$837,933	\$0.0352	C H	1%
------------------	------------	-----------	----------	-----	----

Hyoscine N-butylbromide

<u>Inj 20 mg, 1 ml</u>	85,665	\$163,963	\$1.9140	C H	1%
<u>Tab 10 mg</u>	4,401,087	\$325,680	\$0.0740	C H	1%

Iodine supplement

<u>Tab 150 mcg elemental</u>	5,315,789	\$445,936	\$0.0839	C H	1%
------------------------------	-----------	-----------	----------	-----	----

Iron polymaltose

<u>Inj 50 mg per ml, 2 ml</u>	34,474	\$137,207	\$3.9800	C H	1%
-------------------------------	--------	-----------	----------	-----	----

Iron sucrose

<u>Inj 20 mg per ml, 5 ml ampoule</u>				C H	1%	Not currently listed in Section B of the Pharmaceutical Schedule
---------------------------------------	--	--	--	-----	----	--

Macrogol 3350 with potassium chloride, sodium bicarbonate and sodium chloride

<u>Powder for oral soln 6.563 g with potassium chloride 23.3 mg, sodium bicarbonate 89.3 mg and sodium chloride 175.4 mg</u>				C H	1%	Not currently listed in Section B of the Pharmaceutical Schedule
<u>Powder for oral soln 13.125 g with potassium chloride 46.6 mg, sodium bicarbonate 178.5 mg and sodium chloride 350.7 mg</u>	2,162,914	\$1,307,842	\$0.6047	C H	1%	

Magnesium sulphate

<u>Inj 2 mmol per ml, 5ml</u>				H	1%
-------------------------------	--	--	--	---	----

Mebeverine hydrochloride

<u>Tab 135 mg</u>	1,296,785	\$259,357	\$0.2000	C H	1%
-------------------	-----------	-----------	----------	-----	----

Mesalazine

<u>Suppos 500 mg</u>	128,223	\$146,174	\$1.1400	C H	1%
----------------------	---------	-----------	----------	-----	----

SCHEDULE ONE: PHARMACEUTICALS TO BE TENDERED (DRAFT)

Chemical Name

Line Item	Units	Cost	Unit Subsidy	DV Limit	Comments
Nystatin					
<u>Oral liq 100,000 u per ml</u>	1,468,464	\$195,183	\$0.1329	C H 1%	
Omeprazole					
<u>Powder</u>	6,307	\$53,610	\$8.5000	C H 1%	
<u>Inf 40 mg</u>				H 1%	
<u>Inj 40 mg</u>	2,960	\$16,961	\$5.7300	C H 1%	
<u>Cap 10 mg</u>	4,815,323	\$155,695	\$0.0323	C H 1%	
<u>Cap 20 mg</u>	75,122,680	\$3,155,153	\$0.0420	C H 1%	
<u>Cap 40 mg</u>	20,332,522	\$1,258,357	\$0.0619	C H 1%	
Pancreatic enzyme					
Cap EC 10,000 BP u lipase, 9,000 BP u amylase and 210 BP u protease	1,755,100	\$613,056	\$0.3493	C H 1%	A rebate currently exists
Cap EC 25,000 BP u lipase, 18,000 BP u amylase, 1,000 BP u protease	1,713,337	\$1,617,047	\$0.9438	C H 1%	
Cap EC 25,000 BP u lipase, 22,500 BP u amylase, 1,250 BP u protease	37,680	\$35,570	\$0.9440	C H 1%	
Powder				C H 1%	
Pantoprazole					
Inj 40 mg				C H 1%	Not currently listed in Section B of the Pharmaceutical Schedule
Poloxamer					
<u>Oral drops 10%</u>	256,950	\$32,376	\$0.1260	C H 1%	
Pyridoxine hydrochloride					
<u>Tab 25 mg</u>	238,686	\$5,835	\$0.0244	C H 1%	
<u>Tab 50 mg</u>	2,020,126	\$49,129	\$0.0243	C H 1%	
Ranitidine hydrochloride					
<u>Oral liq 150 mg per 10 ml</u>	1,673,624	\$33,026	\$0.0197	C H 1%	
<u>Tab 150 mg</u>	6,938,229	\$188,442	\$0.0272	C H 1%	
<u>Tab 300 mg</u>	2,229,831	\$83,306	\$0.0374	C H 1%	
Triamcinolone acetonide					
<u>0.1% in Dental Paste USP</u>	116,040	\$100,723	\$0.8680	C H 1%	
Ursodeoxycholic acid					
<u>Cap 250 mg - 300 mg</u>	435,271	\$311,219	\$0.7150	C H 1%	Cap 250mg is currently listed on the Pharmaceutical Schedule. Units shown are for cap 250 mg
Zinc sulphate					
Cap 50 mg elemental	867,416	\$95,416	\$0.1100	C H 1%	

Blood and Blood Forming Organs

SCHEDULE ONE: PHARMACEUTICALS TO BE TENDERED (DRAFT)

Chemical Name

Line Item	Units	Cost	Unit Subsidy		DV Limit	Comments
Deferiprone						
Oral liq 100 mg per 1 ml	11,000	\$11,730	\$1.0664	C H	1%	A rebate currently exists. Delisting and/or subsidy reduction and/or price 30/06/2014
Tab 500 mg	33,340	\$177,759	\$5.3317	C H	1%	A rebate currently exists. Delisting and/or subsidy reduction and/or price 30/06/2014
Dextrose						
<u>Inj 50%, 10 ml</u>	10,171	\$39,667	\$3.9000	C H	1%	
<u>Inj 50%, 50 ml</u>				C H	1%	Not currently listed in Section B of the Pharmaceutical Schedule
<u>Inj 50%, 90 ml</u>	178	\$2,003	\$11.2500	C H	1%	
Dipyridamole						
<u>Tab long-acting 150 mg</u>	8,555,842	\$1,642,722	\$0.1920	C H	1%	
Nicotinic acid						
<u>Tab 50 mg</u>	1,287,381	\$53,684	\$0.0417	C H	1%	
<u>Tab 500 mg</u>	1,062,857	\$175,797	\$0.1654	C H	1%	
Rivaroxaban						
Tab 10 mg	14,982	\$152,816	\$10.2000	C H	1%	A rebate currently exists. Delisting and/or subsidy reduction and/or price protection 30/06/2014
Sodium chloride						
Soln 0.9% for irrigation, 30 ml				H	1%	

Cardiovascular System

Ambrisentan						
Tab 10 mg	450	\$68,775	\$152.8333	C H	1%	A rebate currently exists. Reference pricing protection until 31/12/2014
Tab 5 mg	420	\$64,190	\$152.8333	C H	1%	A rebate currently exists. Reference pricing protection until 31/12/2014
Amlodipine						
<u>Tab 2.5 mg</u>	272,301	\$6,671	\$0.0245	C H	1%	
<u>Tab 5 mg</u>	10,938,919	\$289,881	\$0.0265	C H	1%	
<u>Tab 10 mg</u>	5,188,103	\$215,306	\$0.0415	C H	1%	
Bendroflumethiazide [Bendrofluazide]						
<u>Tab 2.5 mg</u>	30,297,089	\$392,650	\$0.0130	C H	1%	
<u>Tab 5 mg</u>	3,493,889	\$69,528	\$0.0199	C H	1%	
Carvedilol						
Tab 12.5 mg	2,107,863	\$1,897,077	\$0.9000	+ C H	1%	A rebate currently exists
Tab 25 mg	2,499,634	\$2,812,088	\$1.1250	+ C H	1%	A rebate currently exists
Tab 6.25 mg	2,596,760	\$1,817,732	\$0.7000	+ C H	1%	A rebate currently exists

SCHEDULE ONE: PHARMACEUTICALS TO BE TENDERED (DRAFT)

Chemical Name

Line Item	Units	Cost	Unit Subsidy		DV Limit	Comments
Celiprolol						
<u>Tab 200 mg</u>	4,540,477	\$479,273	\$0.1056	C H	1%	Delisting and/or subsidy reduction and/or price protection until 1/07/2014
Doxazosin mesylate						
<u>Tab 2 mg</u>	11,898,139	\$195,843	\$0.0165	C H	1%	
<u>Tab 4 mg</u>	10,106,468	\$250,640	\$0.0248	C H	1%	
Ephedrine hydrochloride						
Inj 30 mg per ml, 1ml				H	1%	
Ezetimibe						
Tab 10 mg	4,140,207	\$4,751,578	\$1.1477	+ C H	1%	A rebate currently exists
Ezetimibe with simvastatin						
Tab 10 mg with simvastatin 10 mg	56,550	\$69,142	\$1.2227	+ C H	1%	A rebate currently exists
Tab 10 mg with simvastatin 20 mg	83,581	\$107,819	\$1.2900	+ C H	1%	A rebate currently exists
Tab 10 mg with simvastatin 40 mg	184,912	\$255,179	\$1.3800	+ C H	1%	A rebate currently exists
Tab 10 mg with simvastatin 80 mg	157,745	\$238,984	\$1.5150	+ C H	1%	A rebate currently exists
Glyceryl trinitrate						
<u>Tab 500 mcg - 600 mcg</u>	63,900	\$5,112	\$0.0800	C H	1%	
<u>TDDS 5 mg</u>	140,777	\$77,709	\$0.5520	C H	1%	
<u>TDDS 10 mg</u>	63,040	\$40,976	\$0.6500	C H	1%	
Isosorbide mononitrate						
<u>Tab 20 mg</u>	625,359	\$106,936	\$0.1710	C H	1%	
<u>Tab long-acting 40 mg</u>	797,697	\$199,424	\$0.2500	C H	1%	
Tab long-acting 60 mg	10,784,797	\$472,134	\$0.0438	C H	1%	Delisting and/or subsidy reduction and/or price protection until 1/07/2014
Labetalol						
Tab 50 mg	219,373	\$18,054	\$0.0823	C H	1%	Delisting and/or subsidy reduction and/or price protection until 1/07/2014
Tab 100 mg	757,741	\$76,229	\$0.1006	C H	1%	Delisting and/or subsidy reduction and/or price protection until 1/07/2014
Tab 200 mg	948,572	\$166,474	\$0.1755	C H	1%	Delisting and/or subsidy reduction and/or price protection until 1/07/2014
Levosimendan						
Inj 2.5 mg per ml, 10 ml vial				H	1%	
Inj 2.5 mg per ml, 5 ml vial				H	1%	
Losartan						
<u>Tab 12.5 mg</u>	1,481,653	\$47,413	\$0.0320	C H	1%	
<u>Tab 25 mg</u>	1,305,617	\$46,422	\$0.0356	C H	1%	
<u>Tab 50 mg</u>	3,363,326	\$195,073	\$0.0580	C H	1%	
<u>Tab 100 mg</u>	1,095,785	\$105,682	\$0.0964	C H	1%	

SCHEDULE ONE: PHARMACEUTICALS TO BE TENDERED (DRAFT)

Chemical Name

Line Item	Units	Cost	Unit Subsidy	DV Limit	Comments
Losartan with hydrochlorothiazide					
<u>Tab 50 mg with hydrochlorothiazide 12.5 mg</u>			\$0.1630	C H 1%	
Milrinone					
Inj 1 mg per ml, 10 ml				H 1%	
Nifedipine					
Tab long-acting 30 mg	530,792	\$151,453	\$0.2853 *	C H 1%	Delisting and/or subsidy reduction and/or price protection until 1/07/2014
Tab long-acting 60 mg	218,786	\$89,556	\$0.4093 *	C H 1%	Delisting and/or subsidy reduction and/or price protection until 1/07/2014
Perindopril					
Tab 2 mg	71,754	\$8,969	\$0.1250	C H 1%	
Tab 4 mg	260,527	\$41,684	\$0.1600	C H 1%	
Pravastatin					
Tab 10 mg				C H 1%	Not currently listed in Section B of the Pharmaceutical Schedule
<u>Tab 20 mg</u>	146,159	\$26,503	\$0.1813	C H 1%	
<u>Tab 40 mg</u>	41,189	\$12,741	\$0.3093	C H 1%	
Propranolol					
Cap long-acting 160 mg	632,132	\$101,520	\$0.1606	C H 1%	Delisting and/or subsidy reduction and/or price protection until 1/07/2014
Tab 10 mg	2,244,811	\$81,936	\$0.0365	C H 1%	Delisting and/or subsidy reduction and/or price protection until 31/03/2014
Tab 40 mg	2,394,361	\$111,338	\$0.0465	C H 1%	Delisting and/or subsidy reduction and/or price protection until 31/03/2014
Sildenafil					
<u>Tab 100 mg</u>	5,675	\$10,570	\$1.8625	C H 1%	
<u>Tab 25 mg</u>	27,645	\$12,786	\$0.4625	C H 1%	
<u>Tab 50 mg</u>	101,847	\$47,104	\$0.4625	C H 1%	
Simvastatin					
<u>Tab 10 mg</u>	8,586,589	\$133,569	\$0.0156	C H 1%	
<u>Tab 20 mg</u>	42,921,679	\$929,970	\$0.0217	C H 1%	
<u>Tab 40 mg</u>	41,061,652	\$1,450,845	\$0.0353	C H 1%	
<u>Tab 80 mg</u>	4,261,353	\$440,813	\$0.1034	C H 1%	
Timolol maleate					
Tab 10 mg	118,260	\$12,476	\$0.1055	C H 1%	
Verapamil hydrochloride					
<u>Tab 40 mg</u>	254,642	\$17,850	\$0.0701	C H 1%	
<u>Tab 80 mg</u>	158,035	\$18,553	\$0.1174	C H 1%	

SCHEDULE ONE: PHARMACEUTICALS TO BE TENDERED (DRAFT)

Chemical Name

Line Item	Units	Cost	Unit Subsidy		DV Limit	Comments
Verapamil hydrochloride						
Tab long-acting 120 mg	1,990,071	\$120,996	\$0.0608	C H	1%	Delisting and/or subsidy reduction and/or price protection until 1/07/2014
Tab long-acting 240 mg	1,531,479	\$153,148	\$0.1000	C H	1%	Delisting and/or subsidy reduction and/or price protection until 1/07/2014

Dermatologicals

Acitretin

Cap 10 mg	369,481	\$238,069	\$0.6443	C H	1%	A rebate currently exists. Delisting and/or subsidy reduction and/or price protection until 30/06/2014
Cap 25 mg	96,980	\$134,333	\$1.3852	C H	1%	A rebate currently exists. Restriction on delisting and/or subsidy reduction and/or price until 30/06/2014

Adapalene

Crn 0.1%	272,520	\$207,933	\$0.7630	C H	1%	A rebate currently exists
Gel 0.1%	498,210	\$380,134	\$0.7630	C H	1%	A rebate currently exists

Amorolfine

Nail soln 5%	2,625	\$19,877	\$7.5720 *	C H	1%	
--------------	-------	----------	------------	-----	----	--

Aqueous Cream

<u>Crn (100 g or less)</u>				H	1%	
<u>Crn (greater than 100 g)</u>	183,295,098	\$718,517	\$0.0039	C H	1%	

Benzoyl peroxide

Soln 5%				H	1%	
---------	--	--	--	---	----	--

Chlorhexidine gluconate

<u>Soln 4%</u>	2,164,198	\$25,538	\$0.0118	C H	1%	
----------------	-----------	----------	----------	-----	----	--

Clotrimazole

<u>Crn 1%</u>	4,463,440	\$120,513	\$0.0270	C H	1%	
---------------	-----------	-----------	----------	-----	----	--

Emulsifying ointment

<u>Oint BP (pack size 100 g or less)</u>	68,545,087	\$416,754	\$0.0061	C H	1%	
<u>Oint BP (pack size greater than 100 g)</u>	68,545,087	\$416,754	\$0.0061	C H	1%	

Hydrocortisone

Crn 1% (pack size greater than 15 g and less than 100 g)	19,086,096	\$715,729	\$0.0375	C H	1%	
<u>Crn 1% (pack size greater than 100 g)</u>	19,086,096	\$715,729	\$0.0375	C H	1%	
<u>Powder</u>	75,756	\$133,331	\$1.7600	C H	1%	

Hydrocortisone with wool fat and mineral oil

<u>Lotn 1% with wool fat hydrous 3% and mineral oil</u>	12,947,933	\$515,328	\$0.0398	C H	1%	
---	------------	-----------	----------	-----	----	--

Hydrogen peroxide

3% (10 vol)				H	1%	
-------------	--	--	--	---	----	--

SCHEDULE ONE: PHARMACEUTICALS TO BE TENDERED (DRAFT)

Chemical Name

Line Item	Units	Cost	Unit Subsidy		DV Limit	Comments
Hydrogen peroxide						
Crn 1%	426,090	\$243,155	\$0.5707	C H	1%	A rebate currently exists
Imiquimod						
<u>Crn 5%</u>	201,464	\$1,040,897	\$5.1667	C H	1%	
Ketoconazole						
<u>Shampoo 2%</u>	4,323,700	\$133,170	\$0.0308	C H	1%	
Lice treatment						
lotn	10,293,400	\$195,060	\$0.0190	C H	1%	Unit Subsidy and Unit Price is for malathion liq 0.5%. A rebate currently exists for malathion
Shampoo	776,220	\$73,223	\$0.0943	C H	1%	Unit Subsidy and Unit Price is for malathion shampoo 1%
Miconazole nitrate						
<u>Crn 2% (15 g - 20 g pack)</u>	1,957,320	\$60,024	\$0.0307	C H	1%	
Mometasone furoate						
Lotn 0.1%	370,380	\$90,743	\$0.2450	C H	1%	Delisting and/or subsidy reduction and/or price protection until 1/06/2014
Permethrin						
<u>Crn 5%</u>	696,210	\$97,469	\$0.1400	C H	1%	
<u>Lotion 5%</u>	3,837,750	\$414,477	\$0.1080	C H	1%	
Tar with triethanolamine lauryl sulphate and fluorescein						
<u>Soln 2.3% with triethanolamine lauryl sulphate and fluorescein sodium</u>	49,837,721	\$304,010	\$0.0061	C H	1%	
Triamcinolone acetonide						
<u>Crn 0.02%</u>	1,053,600	\$69,854	\$0.0663	C H	1%	
<u>Oint 0.02%</u>	585,800	\$39,190	\$0.0669	C H	1%	
Wool fat						
Crn				H	1%	
Zinc						
Oint BP				H	1%	
Crn BP				H	1%	
Zinc and castor Oil						
Oint BP (pack size 30 g or less)	15,469,336	\$118,495	\$0.0077	C H	1%	
Oint BP (pack size greater than 30 g)	15,469,336	\$118,495	\$0.0077	C H	1%	

Extemporaneously Compounded Preparations & Galenicals

Glycerol

Liq BP	1,364,962	\$12,189	\$0.0089	C H	1%	Preference for pack size < 2,000 ml
--------	-----------	----------	----------	-----	----	-------------------------------------

Zinc

Paste, compound BP				H	1%	
--------------------	--	--	--	---	----	--

SCHEDULE ONE: PHARMACEUTICALS TO BE TENDERED (DRAFT)

Chemical Name

Line Item

Units

Cost

Unit Subsidy

DV Limit

Comments

Genito Urinary System

Cyproterone acetate with ethinyloestradiol

Tab 2 mg with ethinyloestradiol 35 mcg and 7 inert tablets 10,397,968 \$481,525 \$0.0463 C H 1%

Ergometrine maleate

Inj 500 mcg per ml, 1 ml 1,915 \$11,873 \$6.2000 C H 1%

Ethinylloestradiol with levonorgestrel

Tab 20 mcg with levonorgestrel 100 mcg and 7 inert tablets 3,741,556 \$131,400 \$0.0351 C 1%

Tab 30 mcg with levonorgestrel 150 mcg and 7 inert tablets 32,045,272 \$934,654 \$0.0292 C 1%

Finasteride

Tab 5 mg 1,584,526 \$269,369 \$0.1700 C H 1%

Miconazole nitrate

Vaginal crm 2% with applicator 568,400 \$39,078 \$0.0688 * C H 1%

Pregnancy tests - hCG urine

Urine diagnostic test 418,880 \$238,762 \$0.5700 C H 1%

Hormone Preparations - Systemic Excluding Contraceptive Hormones

Calcitonin

Inj 100 iu per ml, 1 ml 976 \$21,472 \$22.0000 C H 1%

Desmopressin

Nasal spray 10 mcg per dose 78,552 \$359,768 \$4.5800 C H 1%

Norethisterone

Tab 5 mg 1,411,149 \$373,954 \$0.2650 C H 1%

Testosterone cypionate

Inj long-acting 100 mg per ml, 10 ml 3,999 \$305,924 \$76.5000 C H 1%

Tetracosactrin

Inj 250 mcg 191 \$3,384 \$17.7180 C H 1%

Inj 1 mg per ml, 1 ml 109 \$3,222 \$29.5600 C H 1%

Triamcinolone acetonide

Inj 10 mg per ml, 1 ml 5,417 \$23,726 \$4.3800 C H 1%

Inj 40 mg per ml, 1 ml 66,574 \$716,203 \$10.7580 C H 1%

Infections

Abacavir sulphate

Oral liq 20 mg per ml 30,960 \$6,450 \$0.2083 C H 1%

Tab 300 mg 38,865 \$148,335 \$3.8167 C H 1%

SCHEDULE ONE: PHARMACEUTICALS TO BE TENDERED (DRAFT)

Chemical Name	Units	Cost	Unit Subsidy	DV Limit	Comments
Line Item					
Albendazole					
Tab 200 mg				C H 1%	Not currently listed in Section B of the Pharmaceutical Schedule. Any listing may be subject to Special Authority restriction.
Tab 400mg			\$14.1608	C H 1%	
Amikacin					
Inj 15 mg per ml, 5 ml syringe				H 1%	
Inj 5 mg per ml, 10 ml syringe				H 1%	
<u>Inj 5 mg per ml, 5 ml syringe</u>				H 1%	
Inj 250 mg per ml, 2 ml				H 1%	
Amoxicillin					
<u>Inj 250 mg</u>	431	\$559	\$1.2960	C H 1%	
<u>Inj 500 mg</u>	1,375	\$2,074	\$1.5080	C H 1%	
<u>Inj 1 g</u>	6,436	\$14,121	\$2.1940	C H 1%	
Amoxicillin clavulanate					
<u>Tab amoxicillin 500 mg with potassium clavulanate 125 mg</u>	15,439,860	\$1,937,702	\$0.1255	@ C H 1%	
Amphotericin B					
Inj 50 mg				H 1%	
Artemether with lumefantrine					
Tab 20 mg with lumefantrine 120 mg				H 1%	
Artesunate					
Inj 60 mg				H 1%	
Atovaquone with proguanil hydrochloride					
Tab 250 mg with proguanil hydrochloride 100 mg				H 1%	
Tab 62.5mg with proguanil hydrochloride 25 mg (Paediatric)				H 1%	
Aztreonam					
<u>Inj 1 g</u>				H 1%	
Benzylpenicillin sodium [Penicillin G]					
<u>Inj 600 mg</u>	5,731	\$6,591	\$1.1500	C H 1%	
Cefazolin sodium					
<u>Inj 500 mg</u>	484	\$386	\$0.7980	C H 1%	
<u>Inj 1 g</u>	5,962	\$4,758	\$0.7980	C H 1%	
Cefotaxime					
<u>Inj 500 mg</u>				H 1%	
<u>Inj 1 g</u>				H 1%	
Ceftazidime					
<u>Inj 500 mg</u>				H 1%	

SCHEDULE ONE: PHARMACEUTICALS TO BE TENDERED (DRAFT)

Chemical Name	Line Item	Units	Cost	Unit Subsidy	DV Limit	Comments
Ceftazidime						
	<u>Inj 1 g</u>				H 1%	
	<u>Inj 2 g</u>				H 1%	
Cefuroxime sodium						
	Inj 250 mg			\$2.0970	C H 1%	
	<u>Inj 750 mg</u>	57	\$79	\$1.3920	C H 1%	
	<u>Inj 1.5 g</u>			\$4.0400	C H 1%	
Chloramphenicol						
	Inj 1 g				H 1%	
Chloroquine phosphate						
	Tab 250 mg				H 1%	
Cidofovir						
	Inj 75 mg per ml, 5 ml				H 1%	
Ciprofloxacin						
	<u>Tab 250 mg</u>	327,280	\$25,715	\$0.0786	C H 1%	
	<u>Tab 500 mg</u>	1,632,604	\$174,922	\$0.1071	C H 1%	
	<u>Tab 750 mg</u>	26,115	\$4,805	\$0.1840	C H 1%	
	Oral liq 100mg per ml				H 1%	Tender will be awarded for either 50mg per ml or 100mg per ml.
	Oral liq 50mg per ml				H 1%	Tender will be awarded for either 50mg per ml or 100mg per ml.
Clarithromycin						
	Inj 500 mg				H 1%	
	<u>Tab 250 mg</u>	73,888	\$22,114	\$0.2993	C H 1%	
	<u>Tab 500 mg</u>	105,186	\$82,270	\$0.7821	C H 1%	
Clofazimine						
	Cap 50 mg			\$1.9750	C H 1%	
Cycloserine						
	Cap 250 mg			\$11.4063	C H 1%	
Dapsone						
	Tab 100 mg	44,333	\$48,766	\$1.1000	C H 1%	
	Tab 25 mg	58,524	\$55,598	\$0.9500	C H 1%	
Daptomycin						
	Inj 350 mg vial				H 1%	
Demeclocycline						
	Cap 150 mg				H 1%	
Doxycycline hydrochloride						
	<u>Tab 100 mg</u>	9,542,087	\$303,438	\$0.0318	C H 1%	

SCHEDULE ONE: PHARMACEUTICALS TO BE TENDERED (DRAFT)

Chemical Name						
Line Item	Units	Cost	Unit Subsidy		DV Limit	Comments
Emtricitabine						
Cap 200 mg	291,459	\$2,984,540	\$10.2400	+ C H	1%	
Flucloxacillin sodium						
<u>Inj 250 mg</u>	363	\$394	\$1.0860	C H	1%	
<u>Inj 500 mg</u>	1,186	\$1,343	\$1.1320	C H	1%	
<u>Inj 1 g</u>	12,320	\$17,593	\$1.4280	C H	1%	
Fluconazole						
<u>Cap 50 mg</u>	160,121	\$27,278	\$0.1704	C H	1%	
<u>Cap 150 mg</u>	31,097	\$28,298	\$0.9100	C H	1%	
<u>Cap 200 mg</u>	66,667	\$31,762	\$0.4764	C H	1%	
Flucytosine						
Cap 500 mg				H	1%	
Foscarnet sodium						
Inj 24 mg per ml, 250 ml				H	1%	
Hexamine hippurate						
Tab 1 g	177,795	\$32,714	\$0.1840	* C H	1%	
Imipenem with cilastatin						
<u>Inj 500 mg with cilastatin 500 mg</u>				H	1%	
Indinavir						
Cap 200 mg			\$1.4438	C H	1%	
Cap 400 mg	1,740	\$5,024	\$2.8875	C H	1%	
Isoniazid with rifampicin						
Tab 100 mg with rifampicin 150 mg	17,536	\$15,789	\$0.9004	C H	1%	
Tab 150 mg with rifampicin 300 mg	108,217	\$194,325	\$1.7957	C H	1%	
Itraconazole						
Oral liq 10 mg per ml			\$0.9453	C H	1%	
Ketoconazole						
Tab 200 mg	27,429	\$34,853	\$1.2707	C H	1%	
Lamivudine						
Oral liq 5 mg per ml	10,190	\$3,821	\$0.3750	C H	1%	
Tab 100 mg	249,495	\$289,592	\$1.1607	+ C H	1%	
Lincomycin						
Inj 300 mg per ml, 2 ml			\$16.0000	C H	1%	
Linezolid						
Inj 2 mg per ml, 300 ml				H	1%	
Oral liq 20 mg per ml				H	1%	
Tab 600 mg				H	1%	

SCHEDULE ONE: PHARMACEUTICALS TO BE TENDERED (DRAFT)

Chemical Name

Line Item	Units	Cost	Unit Subsidy	DV Limit	Comments
Mebendazole					
Oral liq 100 mg per 5 ml	45,518	\$6,615	\$0.1453 *	C H 1%	
<u>Tab 100 mg</u>	34,325	\$34,597	\$1.0079	C H 1%	
Mefloquine hydrochloride					
Tab 250 mg				H 1%	
Meropenem					
Inj 500 mg				H 1%	
Inj 1 g				H 1%	
Nitazoxanide					
Oral liquid 100mg per 5ml				H 1%	
Nitrofurantoin					
Tab 50 mg	1,882,092	\$417,824	\$0.2220	C H 1%	
Tab 100 mg	666,295	\$249,861	\$0.3750	C H 1%	
Norfloxacin					
<u>Tab 400 mg</u>	741,546	\$114,569	\$0.1545	C H 1%	
Ornidazole					
Tab 500 mg	142,512	\$235,145	\$1.6500	C H 1%	Delisting and/or subsidy reduction and/or price protection until 30/06/2014
Pentamidine isethionate					
Inj 300 mg				C H 1%	Not currently listed in Section B of the Pharmaceutical Schedule
Praziquantel					
Tab 600mg			\$8.5000	C H 1%	
Primaquine phosphate					
Tab 7.5 mg			\$2.0893	C H 1%	
Procaine penicillin					
Inj 1.5 mega u	2,069	\$51,104	\$24.7000	C H 1%	
Pyrazinamide					
Tab 500 mg	75,788	\$44,715	\$0.5900	C H 1%	
Pyrimethamine					
Tab 25 mg				H 1%	
Quinine dihydrochloride					
Inj 300mg per ml, 2 ml vial				H 1%	
Inj 60 mg per ml, 10 ml ampoule				H 1%	
Rifampicin					
Cap 150 mg	55,566	\$32,595	\$0.5866	C H 1%	
Cap 300 mg	109,188	\$133,602	\$1.2236	C H 1%	
Inj 600 mg				H 1%	

SCHEDULE ONE: PHARMACEUTICALS TO BE TENDERED (DRAFT)

Chemical Name

Line Item	Units	Cost	Unit Subsidy	DV Limit	Comments
Rifampicin					
Oral liq 100 mg per 5 ml	117,940	\$24,885	\$0.2110	C H 1%	
Tab 600 mg	15,513	\$59,156	\$3.8133	C H 1%	
Ritonavir					
Oral liq 80 mg per ml			\$1.1553	C H 1%	
Sodium stibogluconate					
Inj 100 mg per ml				H 1%	
Spiramycin					
Tab 500 mg				C H 1%	Not currently listed in Section B of the Pharmaceutical Schedule
Streptomycin sulphate					
Inj 400mg per ml, 2.5ml ampoule				H 1%	
Sulphadiazine					
Tab 500mg				C H 1%	Not currently listed in Section B of the Pharmaceutical Schedule
Terbinafine					
<u>Tab 250 mg</u>	1,940,232	\$246,687	\$0.1271	C H 1%	
Ticarcillin with clavulanic acid					
Inj 3g with clavulanic acid 0.1 mg vial				H 1%	
Tigecycline					
Inj 50mg vial				H 1%	
Tobramycin					
<u>Inj 40 mg per ml, 2 ml</u>	35,140	\$206,061	\$5.8640	C H 1%	
Inj 100mg per ml, 5ml vial			\$0.0000	C H 1%	
Trimethoprim					
Tab 100 mg				C H 1%	Not currently listed in Section B of the Pharmaceutical Schedule
Trimethoprim with sulphamethoxazole [Co-trimoxazole]					
Inj 16mg with sulphamethoxazole 80mg per ml, 5ml ampoule				H 1%	
Vancomycin hydrochloride					
<u>Inj 500 mg</u>	5,926	\$21,215	\$3.5800	C H 1%	
Zidovudine [AZT]					
Inj 10 mg per ml, 20 ml vial				C H 1%	
Zidovudine [AZT] with lamivudine					
<u>Tab 300 mg with lamivudine 150 mg</u>	186,414	\$2,072,924	\$11.1200	C H 1%	

Musculoskeletal System

Allopurinol

<u>Tab 100 mg</u>	17,359,390	\$276,014	\$0.0159	C H 1%	
-------------------	------------	-----------	----------	--------	--

SCHEDULE ONE: PHARMACEUTICALS TO BE TENDERED (DRAFT)

Chemical Name	Units	Cost	Unit Subsidy	DV Limit	Comments
Line Item					
Allopurinol					
<u>Tab 300 mg</u>	11,801,906	\$395,364	\$0.0335	C H	1%
Auranofin					
Tab 3 mg	6,316	\$7,262	\$1.1498	C H	1%
Celecoxib					
Cap 100 mg				+ C H	1% Not currently listed in Section B of the Pharmaceutical Schedule
Cap 200 mg				+ C H	1% Not currently listed in Section B of the Pharmaceutical Schedule
Cap 400 mg				+ C H	1% Not currently listed in Section B of the Pharmaceutical Schedule
Diclofenac sodium					
<u>Inj 25 mg per ml, 3 ml</u>	23,998	\$57,595	\$2.4000	C H	1%
<u>Suppos 12.5 mg</u>	6,796	\$1,257	\$0.1850	C H	1%
<u>Suppos 25 mg</u>	8,528	\$1,893	\$0.2220	C H	1%
<u>Suppos 50 mg</u>	66,628	\$25,585	\$0.3840	C H	1%
<u>Suppos 100 mg</u>	139,487	\$88,714	\$0.6360	C H	1%
Etanercept					
Inj 50 mg autoinjector	16,247	\$7,717,000	\$474.9800	C H	1% A rebate currently exists
Inj 50 mg prefilled syringe	2,262	\$1,074,405	\$474.9800	C H	1% A rebate currently exists
Etoricoxib					
Tab 120 mg				C H	1% Not currently listed in Section B of the Pharmaceutical Schedule
Tab 30 mg				C H	1% Not currently listed in Section B of the Pharmaceutical Schedule
Tab 60 mg				C H	1% Not currently listed in Section B of the Pharmaceutical Schedule
Tab 90 mg				C H	1% Not currently listed in Section B of the Pharmaceutical Schedule
Ibuprofen					
<u>Tab 200 mg</u>	40,016,480	\$510,210	\$0.0128	C H	1%
<u>Tab long-acting 800 mg</u>	6,851,707	\$1,854,529	\$0.2707	C H	1%
Ketoprofen					
Cap long-acting 100 mg	101,918	\$21,974	\$0.2156	C H	1% Delisting and/or subsidy reduction and/or price protection until 1/07/2014
Cap long-acting 200 mg	100,883	\$43,501	\$0.4312	C H	1% Delisting and/or subsidy reduction and/or price protection until 1/07/2014
Mefenamic acid					
Cap 250 mg	407,007	\$10,175	\$0.0250 *	C H	1%

SCHEDULE ONE: PHARMACEUTICALS TO BE TENDERED (DRAFT)

Chemical Name

Line Item	Units	Cost	Unit Subsidy	DV Limit	Comments
Meloxicam					
Tab 7.5 mg	15,813	\$6,062	\$0.3833	C H	1%
Neostigmine					
<u>Inj 2.5 mg per ml, 1 ml</u>	24,588	\$68,846	\$2.8000	C H	1%
Pamidronate disodium					
Inj 3 mg per ml, 5 ml	1	\$19	\$18.7500	C H	1%
<u>Inj 3 mg per ml, 10 ml</u>	1,878	\$30,048	\$16.0000	C H	1%
<u>Inj 6 mg per ml, 10 ml</u>	124	\$3,968	\$32.0000	C H	1%
<u>Inj 9 mg per ml, 10 ml</u>	289	\$13,872	\$48.0000	C H	1%
Pyridostigmine bromide					
<u>Tab 60 mg</u>	470,181	\$182,900	\$0.3890	C H	1%
Tiaprofenic acid					
Tab 300 mg	95,195	\$30,558	\$0.3210	C H	1% Delisting and/or subsidy reduction and/or price protection until 1/07/2014

Nervous System

Alfentanil					
Inj 0.5 mg per ml, 2 ml ampoule				H	1%
Amantadine hydrochloride					
<u>Cap 100 mg</u>	637,226	\$406,125	\$0.6373	C H	1%
Amitriptyline					
<u>Tab 10 mg</u>	16,599,740	\$551,111	\$0.0332	C H	1%
<u>Tab 25 mg</u>	8,067,507	\$149,249	\$0.0185	C H	1%
<u>Tab 50 mg</u>	2,393,938	\$86,182	\$0.0360	C H	1%
Aprepitant					
Cap 2 x 80 mg and 1 x 125 mg	14,598	\$564,456	\$38.6667	C H	1% Delisting and/or subsidy reduction and/or price protection until 1/07/2014
Benzocaine					
Gel 20%				H	1%
Betahistine dihydrochloride					
Tab 16 mg	2,016,603	\$240,072	\$0.1190	C H	1%
Bupivacaine hydrochloride					
Inj 1.25 mg per ml, 100 ml bag				H	1%
Inj 1.25 mg per ml, 200 ml bag				H	1%
Inj 2.5 mg per ml, 100 ml bag				H	1%
Inj 2.5 mg per ml, 200 ml bag				H	1%
Inj 5 mg per ml, 4 ml				H	1%
Bupivacaine hydrochloride with adrenaline					
<u>Inj 0.25% with 1:400,000 of adrenaline, 20 ml sterile pack</u>				H	1%

SCHEDULE ONE: PHARMACEUTICALS TO BE TENDERED (DRAFT)

Chemical Name

Line Item	Units	Cost	Unit Subsidy	DV Limit	Comments
Bupivacaine hydrochloride with adrenaline					
<u>Inj 0.5% with 1:200,000 of adrenaline, 20 ml sterile pack</u>				H 1%	
Bupivacaine hydrochloride with fentanyl					
Inj 0.625 mg with fentanyl 2 mcg per ml, 100 ml bag				H 1%	
Inj 1.25 mg with fentanyl 2 mcg per ml, 100 ml syringe				H 1%	
Inj 1.25 mg with fentanyl 2 mcg per ml, 50 ml syringe				H 1%	
<u>Inj 0.125% with 2 mcg fentanyl per ml, 15 ml syringe</u>				H 1%	
<u>Inj 0.125% with 2 mcg fentanyl per ml, 20 ml syringe</u>				H 1%	
<u>Inf 0.125% with 2 mcg fentanyl per ml, 100 ml bag</u>				H 1%	
<u>Inf 0.125% with 2 mcg fentanyl per ml, 200 ml bag</u>				H 1%	
Bupivacaine hydrochloride with glucose					
Inj 0.5% with glucose 8%, 4 ml ampoule				H 1%	
Buspirone hydrochloride					
Tab 5 mg	244,896	\$68,571	\$0.2800	C H	1%
Tab 10 mg	457,040	\$77,697	\$0.1700	C H	1%
Citalopram hydrobromide					
<u>Tab 20 mg</u>	35,153,499	\$979,276	\$0.0279	C H	1%
Clonazepam					
Tab 2 mg	1,035,803	\$132,065	\$0.1275	C H	1%
Tab 500 mcg	6,287,693	\$420,018	\$0.0668	C H	1%
Cocaine hydrochloride					
Paste 5%				H	1%
Soln 15%, 2 ml syringe				H	1%
Soln 4%, 2 ml syringe				H	1%
Cocaine hydrochloride with adrenaline					
Paste 15% with adrenaline 0.06%				H	1%
Paste 25% with adrenaline 0.06%				H	1%
Cyclizine lactate					
Inj 50 mg per ml, 1 ml	58,855	\$175,976	\$2.9900	C H	1%
Dexmedetomidine hydrochloride					
Inj 100mcg per ml, 2 ml vial				H	1%
Diazepam					
Tab 2 mg	2,853,243	\$65,282	\$0.0229	C H	1%
Tab 5 mg	4,346,491	\$119,181	\$0.0274	C H	1%

SCHEDULE ONE: PHARMACEUTICALS TO BE TENDERED (DRAFT)

Chemical Name	Units	Cost	Unit Subsidy	DV Limit	Comments
Donepezil hydrochloride					
Tab 5 mg	771,044	\$66,053	\$0.0857	C H	1%
Tab 10 mg	675,426	\$105,517	\$0.1562	C H	1%
Doxepin hydrochloride					
Cap 10 mg	1,568,456	\$98,813	\$0.0630	C H	1%
Cap 25 mg	2,135,280	\$146,480	\$0.0686	C H	1%
Cap 50 mg	903,488	\$77,248	\$0.0855	C H	1%
Ephedrine					
Inj 3 mg per ml, 10 ml prefilled syringe				H	1%
<u>Inj 30 mg per ml, 1 ml ampoule</u>				H	1%
Ethyl chloride					
Spray 100%				H	1%
Etomidate					
Inj 2 mg per ml, 10 ml				H	1%
Fentanyl					
10 mcg per ml, 10 ml syringe				H	1%
<u>10 mcg per ml, 100 ml premixed bag</u>				H	1%
<u>10 mcg per ml, 50 ml prefilled syringe</u>				H	1%
<u>10 mcg per ml, 50 ml premixed bag</u>				H	1%
20 mcg per ml, 100 ml bag				H	1%
<u>20 mcg per ml, 50 ml prefilled syringe</u>				H	1%
Ketamine					
Inj 100 mg per ml, 2 ml vial				H	1%
Inj 1 mg per ml, 100 ml bag				H	1%
Inj 10 mg per ml, 10 ml syringe				H	1%
Inj 4 mg per ml, 50 ml syringe				H	1%
Lidocaine [lignocaine] hydrochloride					
<u>Oral [viscous] soln 2%</u>	482,612	\$132,718	\$0.2750	C H	1%
Lidocaine [lignocaine] hydrochloride with adrenaline					
Inj 1% with adrenaline 1:100,000, 5 ml ampoule				H	1%
Inj 1% with adrenaline 1:200,000, 20 ml vial				H	1%
Inj 2% with adrenaline 1:200,000, 20 ml vial				H	1%
Inj 2% with adrenaline 1:80,000, 1.7 ml dental cartridge				H	1%
Inj 2% with adrenaline 1:80,000, 1.8 ml dental cartridge				H	1%
Inj 2% with adrenaline 1:80,000, 2.2 ml dental cartridge				H	1%

SCHEDULE ONE: PHARMACEUTICALS TO BE TENDERED (DRAFT)

Chemical Name

Line Item	Units	Cost	Unit Subsidy	DV Limit	Comments
Lidocaine [lignocaine] hydrochloride with adrenaline and tetracaine hydrochloride					
Soln 4% with adrenaline 0.1 % and tetracaine hydrochloride 0.5%, 5 ml syringe				H 1%	
Lidocaine [lignocaine] hydrochloride with phenylephrine hydrochloride					
Nasal spray 5% with phenylephrine hydrochloride 0.5%				H 1%	
Lidocaine [lignocaine] with prilocaine hydrochloride					
Crn 2.5% with prilocaine hydrochloride 2.5% 5 g	1,626	\$14,634	\$9.0000	C H 1%	
Crn 2.5% with prilocaine hydrochloride 2.5% 30 g	7,530	\$11,295	\$1.5000	C H 1%	
Patch 25mcg with prilocaine 25mcg				H 1%	
Lithium carbonate					
<u>Cap 250 mg</u>	2,113,846	\$199,124	\$0.0942	C H 1%	
Maprotiline Hydrochloride					
Tab 25 mg	69,545	\$17,428	\$0.2506	C H 1%	
Tab 75 mg	12,804	\$8,967	\$0.7003	C H 1%	
Mepivacaine hydrochloride					
Inj 3%, 1.8ml dental cartridge				H 1%	
Inj 3%, 2.2ml dental cartridge				H 1%	
Methadone hydrochloride					
Inj 10 mg per ml, 1 ml	28,010	\$170,861	\$6.1000	C H 1%	
Methohexital sodium					
Inj 10 mg per ml, 50 ml				H 1%	
Metoclopramide hydrochloride					
<u>Inj 5 mg per ml, 2 ml ampoule</u>	240,157	\$108,071	\$0.4500	C H 1%	
Oral liq 5 mg per 5 ml			\$0.0000	C H 1%	
<u>Tab 10 mg</u>	6,085,098	\$240,361	\$0.0395	C H 1%	
Mianserin hydrochloride					
Tab 30 mg	137,576	\$114,005	\$0.8287	C H 1%	Special Authority will be removed from 1 August 2013
Morphine sulphate					
<u>Inj 1 mg per ml, 100 ml bag</u>				H 1%	
Inj 1 mg per ml, 2 ml syringe				H 1%	
Inj 10 mg per ml, 100 mg cassette				H 1%	
Inj 10 mg per ml, 100 ml bag				H 1%	
Inj 200 mcg in 0.4 ml syringe				H 1%	
Inj 300 mcg in 0.3 ml syringe				H 1%	
<u>Inj 1 mg per ml, 10 ml syringe</u>				H 1%	
<u>Inj 1 mg per ml, 50 ml syringe</u>				H 1%	
<u>Inj 2 mg per ml, 30 ml syringe</u>				H 1%	

SCHEDULE ONE: PHARMACEUTICALS TO BE TENDERED (DRAFT)

Chemical Name

Line Item	Units	Cost	Unit Subsidy	DV Limit	Comments
Morphine sulphate					
<u>Inj 5 mg per ml, 1 ml ampoule</u>	45,669	\$50,327	\$1.1020	C H 1%	
<u>Inj 10 mg per ml 1 ml ampoule</u>	188,053	\$180,155	\$0.9580	C H 1%	
<u>Inj 15 mg per ml, 1 ml ampoule</u>	8,955	\$8,973	\$1.0020	C H 1%	
<u>Inj 30 mg per ml, 1 ml ampoule</u>	67,474	\$71,522	\$1.0600	C H 1%	
Nitrazepam					
Tab 5 mg	642,643	\$32,004	\$0.0498	C H 1%	
Ondansetron					
Tab disp 4 mg	358,553	\$615,994	\$1.7180	C H 1%	
Tab disp 8 mg	127,098	\$25,420	\$0.2000	C H 1%	
Oxazepam					
<u>Tab 10 mg</u>	1,012,751	\$59,651	\$0.0589	C H 1%	
<u>Tab 15 mg</u>	356,454	\$28,980	\$0.0813	C H 1%	
Oxycodone hydrochloride					
Inj 1 mg per ml, 100 ml bag				H 1%	
Paracetamol					
Tab soluble 500 mg				H 1%	Not currently listed in Section B of the Pharmaceutical Schedule
Inj 10 mg per ml, 50 ml				H 1%	
Inj 10 mg per ml, 100 ml				H 1%	
<u>Oral liq 120 mg per 5 ml</u>	107,919,268	\$477,003	\$0.0044	C H 20%	
<u>Oral liq 250 mg per 5 ml</u>	168,093,167	\$1,126,224	\$0.0067	C H 20%	
<u>Tab 500 mg</u>	309,866,345	\$2,906,546	\$0.0094	C H 1%	Preference may be given for suppliers who are able to supply both bottle and blister packs. Bid prices should reflect prices for (a) blister packs only or (b) blister packs and bottle packs or (c) bottle packs only.
Paracetamol with codeine					
<u>Tab paracetamol 500 mg with codeine phosphate 8 mg</u>	51,678,343	\$1,395,315	\$0.0270	C H 1%	
Pergolide					
<u>Tab 0.25 mg</u>	70,504	\$33,842	\$0.4800	C H 1%	
<u>Tab 1 mg</u>	24,986	\$42,476	\$1.7000	C H 1%	
Pethidine hydrochloride					
Inj 5 mg per ml, 10 ml				H 1%	
Inj 10 mg per ml, 100 ml bag				H 1%	
Inj 10 mg per ml, 50 ml syringe				H 1%	
Inj 5 mg per ml, 100 ml bag				H 1%	
<u>Inj 50 mg per ml, 1 ml</u>	11,058	\$12,186	\$1.1020	C H 1%	

SCHEDULE ONE: PHARMACEUTICALS TO BE TENDERED (DRAFT)

Chemical Name	Units	Cost	Unit Subsidy	DV Limit	Comments
Line Item					
Pethidine hydrochloride					
Inj 50 mg per ml, 2 ml	37,748	\$44,014	\$1.1660	C H	1%
Pregabalin					
Cap 100 mg				+ C H	1% Not currently listed in Section B of the Pharmaceutical Schedule. Any listing may be subject to a Special Authority restriction.
Cap 150 mg				+ C H	1% Not currently listed in Section B of the Pharmaceutical Schedule. Any listing may be subject to a Special Authority restriction.
Cap 200 mg				+ C H	1% Not currently listed in Section B of the Pharmaceutical Schedule. Any listing may be subject to a Special Authority restriction.
Cap 225 mg				+ C H	1% Not currently listed in Section B of the Pharmaceutical Schedule. Any listing may be subject to a Special Authority restriction.
Cap 25 mg				+ C H	1% Not currently listed in Section B of the Pharmaceutical Schedule. Any listing may be subject to a Special Authority restriction.
Cap 300 mg				+ C H	1% Not currently listed in Section B of the Pharmaceutical Schedule. Any listing may be subject to a Special Authority restriction.
Cap 50 mg				+ C H	1% Not currently listed in Section B of the Pharmaceutical Schedule. Any listing may be subject to a Special Authority restriction.
Cap 75 mg				+ C H	1% Not currently listed in Section B of the Pharmaceutical Schedule. Any listing may be subject to a Special Authority restriction.
Prilocaine hydrochloride with felypressin					
Inj 3% with felypressin 0.03 iu per ml, 1.8 ml dental cartridge				H	1%
Inj 3% with felypressin 0.03 iu per ml, 2.2 ml dental cartridge				H	1%
Propofol					
Inj 10 mg per ml, 100 ml vial				H	1%
Inj 10 mg per ml, 20 ml ampoule				H	1%
Inj 10 mg per ml, 20 ml vial				H	1%
Inj 10 mg per ml, 50 ml syringe				H	1%

SCHEDULE ONE: PHARMACEUTICALS TO BE TENDERED (DRAFT)

Chemical Name

Line Item	Units	Cost	Unit Subsidy	DV Limit	Comments
Propofol					
Inj 10 mg per ml, 50 ml vial				H 1%	
Quetiapine					
Tab 100 mg	3,143,758	\$733,544	\$0.2333	C H 1%	
Tab 200 mg	1,394,640	\$557,856	\$0.4000	C H 1%	
Tab 25 mg	12,232,934	\$1,427,176	\$0.1167	C H 1%	
Tab 300 mg	392,064	\$261,376	\$0.6667	C H 1%	
Remifentanyl hydrochloride					
<u>Inj 1 mg</u>				H 1%	
<u>Inj 2 mg</u>				H 1%	
Risperidone					
Oral liquid 1 mg per ml	232,099	\$141,967	\$0.6117	C H 1%	Rebate currently exists
Orally-disintegrating tablets 0.5 mg	24,243	\$18,546	\$0.7650	C H 1%	Rebate currently exists
Orally-disintegrating tablets 1 mg	36,739	\$56,211	\$1.5300	C H 1%	Rebate currently exists
Orally-disintegrating tablets 2 mg	62,576	\$191,550	\$3.0611	C H 1%	Rebate currently exists
Tab 0.5 mg	2,121,754	\$124,123	\$0.0585	C H 1%	Rebate currently exists
Tab 1 mg	2,118,009	\$211,801	\$0.1000	C H 1%	Rebate currently exists
Tab 2 mg	1,030,392	\$188,905	\$0.1833	C H 1%	Rebate currently exists
Tab 3 mg	496,531	\$124,133	\$0.2500	C H 1%	Rebate currently existsv
Tab 4 mg	251,219	\$83,740	\$0.3333	C H 1%	Rebate currently exists
Rizatriptan					
<u>Tab orodispersible 10 mg</u>	849,092	\$509,455	\$0.6000	C H 1%	
Ropivacaine hydrochloride					
Inf 2 mg per ml, 100 ml, sterile pack				H 1%	
Inf 2 mg per ml, 200 ml, sterile pack				H 1%	
Inj 10 mg per ml, 10 ml, sterile pack				H 1%	
Inj 10 mg per ml, 20 ml, sterile pack				H 1%	
Inj 2 mg per ml, 10 ml, sterile pack				H 1%	
Inj 2 mg per ml, 20 ml, sterile pack				H 1%	
Inj 7.5 mg per ml, 10 ml, sterile pack				H 1%	
Inj 7.5 mg per ml, 20 ml, sterile pack				H 1%	
Inj 2 mg per ml, 10 ml				H 1%	
Inj 2 mg per ml, 20 ml				H 1%	
Inf 2 mg per ml, 100 ml				H 1%	
Inf 2 mg per ml, 200 ml				H 1%	
Inj 7.5 mg per ml, 10 ml				H 1%	
Inj 7.5 mg per ml, 20 ml				H 1%	
Inj 10 mg per ml, 10 ml				H 1%	

SCHEDULE ONE: PHARMACEUTICALS TO BE TENDERED (DRAFT)

Chemical Name	Units	Cost	Unit Subsidy	DV Limit	Comments
Line Item					
Ropivacaine hydrochloride					
Inj 10 mg per ml, 20 ml				H 1%	
Ropivacaine hydrochloride with fentanyl					
Inf 2 mg per ml with 2 mcg of fentanyl per ml, 100 ml, sterile pack				H 1%	
Inf 2 mg per ml with 2 mcg of fentanyl per ml, 200 ml, sterile pack				H 1%	
Inf 2 mg per ml with 2 mcg of fentanyl per ml, 100 ml				H 1%	
Inf 2 mg per ml with 2 mcg of fentanyl per ml, 200 ml				H 1%	
Suxamethonium chloride					
Inj 50 mg per ml, 2 ml				H 1%	
Temazepam					
<u>Tab 10 mg</u>	4,260,526	\$216,435	\$0.0508	C H 1%	
Tetracaine [amethocaine] hydrochloride					
Gel 4%				H 1%	
Thiopental [Thiopentone] sodium					
Inj 500 mg				H 1%	
Tolcapone					
<u>Tab 100 mg</u>	120,533	\$152,113	\$1.2620	C H 1%	
Tramadol hydrochloride					
Inj 10 mg per ml, 100 ml bag				H 1%	
<u>Cap 50 mg</u>	25,412,371	\$1,257,912	\$0.0495	C H 1%	
Inj 50 mg per ml, 1 ml				H 1%	
Inj 50 mg per ml, 2 ml				H 1%	
Oral drops 100 mg per ml				C H 1%	Not currently listed in Section B of the Pharmaceutical Schedule
Tab sustained release 100 mg			\$0.1070	C H 1%	A rebate currently exists
Tab sustained release 150 mg			\$0.1605	C H 1%	A rebate currently exists
Tab sustained release 200 mg			\$0.2140	C H 1%	A rebate currently exists
Zopiclone					
Tab 7.5 mg (pack size of 30 tablets or less)	22,021,307	\$1,394,683	\$0.0633	C H 1%	
<u>Tab 7.5 mg (pack size greater than 30 tablets)</u>	22,021,307	\$1,394,683	\$0.0633	C H 1%	
Zuclophenthixol hydrochloride					
Tab 2 mg				C H 1%	Not currently listed in Section B of the Pharmaceutical Schedule
Tab 10 mg	91,584	\$28,803	\$0.3145	C H 1%	A rebate currently exists
Tab 25 mg				C H 1%	Not currently listed in Section B of the Pharmaceutical Schedule

SCHEDULE ONE: PHARMACEUTICALS TO BE TENDERED (DRAFT)

Chemical Name

Line Item	Units	Cost	Unit Subsidy	DV Limit	Comments
Zuclopenthixol hydrochloride					
Tab 40 mg				C H 1%	Not currently listed in Section B of the Pharmaceutical Schedule

Oncology Agents and Immunosuppressants

Bicalutamide

Tab 50 mg	195,765	\$69,916	\$0.3571	C H 1%	
-----------	---------	----------	----------	--------	--

Calcium folinate

Inj 50 mg	532	\$2,607	\$4.9000	C H PCT 1%	Preference for products where stability data >48 hours post-compounding
-----------	-----	---------	----------	------------	---

Inj 100 mg				H PCT 1%	Preference for products where stability data >48 hours post-compounding
------------	--	--	--	----------	---

Inj 300 mg				H PCT 1%	Preference for products where stability data >48 hours post-compounding
------------	--	--	--	----------	---

Inj 1 g				H PCT 1%	Preference for products where stability data >48 hours post-compounding
---------	--	--	--	----------	---

Tab 15 mg	4,303	\$35,478	\$8.2450	C H PCT 1%	Preference for products where stability data >48 hours post-compounding
-----------	-------	----------	----------	------------	---

Cisplatin

Inj 1 mg per ml, 100 ml				H 1%	Preference for products where stability data >48 hours post-compounding
-------------------------	--	--	--	------	---

Inj 1 mg per ml, 50 ml				H 1%	Preference for products where stability data >48 hours post-compounding
------------------------	--	--	--	------	---

Cyclophosphamide

Inj 1 g				H PCT 1%	
---------	--	--	--	----------	--

Inj 2 g				H PCT 1%	
---------	--	--	--	----------	--

Docetaxel

Inj 20 mg				H PCT 1%	Preference for products where stability data >48 hours post-compounding
-----------	--	--	--	----------	---

Inj 80 mg				H PCT 1%	Preference for products where stability data >48 hours post-compounding
-----------	--	--	--	----------	---

Etoposide phosphate

Inj 100 mg (of etoposide base)				H PCT 1%	Preference for products where stability data >48 hours post-compounding
--------------------------------	--	--	--	----------	---

Exemestane

Tab 25 mg	142,360	\$107,102	\$0.7523	C H 1%	
-----------	---------	-----------	----------	--------	--

Fludarabine phosphate

Inj 50 mg				H PCT 1%	Preference for products where stability data >48 hours post-compounding
-----------	--	--	--	----------	---

SCHEDULE ONE: PHARMACEUTICALS TO BE TENDERED (DRAFT)

Chemical Name	Units	Cost	Unit Subsidy	DV Limit	Comments
Fluorouracil sodium					
Inj 25 mg per ml, 100 ml				H PCT 1%	Preference for products where stability data >48 hours post-compounding
Inj 50 mg per ml, 10 ml				H PCT 1%	Preference for products where stability data >48 hours post-compounding
Inj 50 mg per ml, 20 ml				H PCT 1%	Preference for products where stability data >48 hours post-compounding
Inj 50 mg per ml, 50 ml				H PCT 1%	Preference for products where stability data >48 hours post-compounding
Inj 50 mg per ml, 100 ml				H PCT 1%	Preference for products where stability data >48 hours post-compounding
Gemcitabine hydrochloride					
Inj 200 mg				H PCT 1%	Preference for products where stability data >48 hours post-compounding
Inj 1 g				H PCT 1%	Preference for products where stability data >48 hours post-compounding
Lomustine					
Cap 10 mg				H PCT 1%	Preference for products where stability data >48 hours post-compounding
Cap 40 mg				H PCT 1%	Preference for products where stability data >48 hours post-compounding
Methotrexate					
Inj 100 mg per ml, 10 ml	776	\$19,400	\$25.0000	C H PCT 1%	Preference for products where stability data >48 hours post-compounding
Inj 100 mg per ml, 50 ml			\$125.0000	C H PCT 1%	Preference for products where stability data >48 hours post-compounding
Mitozantrone					
Inj 2 mg per ml, 12.5 ml				H PCT 1%	Preference for products where stability data >48 hours post-compounding
Inj 2 mg per ml, 5 ml				H PCT 1%	Preference for products where stability data >48 hours post-compounding
Inj 2 mg per ml, 10 ml				H PCT 1%	Preference for products where stability data >48 hours post-compounding
Octreotide (somatostatin analogue)					
<u>Inj 50 mcg per ml, 1 ml</u>	1,092	\$4,202	\$3.8480	C H 1%	
<u>Inj 100 mcg per ml, 1 ml</u>	8,885	\$64,647	\$7.2760	C H 1%	
<u>Inj 500 mcg per ml, 1 ml</u>	3,112	\$81,690	\$26.2500	C H 1%	
LAR inj 10 mg	252	\$446,670	\$1,772.5000	C H 1%	A rebate currently exists
LAR inj 20 mg	1,562	\$3,684,368	\$2,358.7500	C H 1%	A rebate currently exists
LAR inj 30 mg	1,206	\$3,559,208	\$2,951.2500	C H 1%	A rebate currently exists

SCHEDULE ONE: PHARMACEUTICALS TO BE TENDERED (DRAFT)

Chemical Name	Line Item	Units	Cost	Unit Subsidy	DV Limit	Comments
Paclitaxel						
	Inj 30 mg				H PCT 1%	Preference for products where stability data >48 hours post-compounding
	Inj 100 mg				H PCT 1%	Preference for products where stability data >48 hours post-compounding
	Inj 150 mg				H PCT 1%	Preference for products where stability data >48 hours post-compounding
	Inj 300 mg				H PCT 1%	Preference for products where stability data >48 hours post-compounding
	Inj 600 mg				H PCT 1%	Preference for products where stability data >48 hours post-compounding
Tamoxifen citrate						
	Tab 10 mg	38,410	\$6,722	\$0.1750	C H 1%	
	<u>Tab 20 mg</u>	1,539,979	\$134,748	\$0.0875	C H 1%	

Respiratory System and Allergies

Aminophylline						
	<u>Inj 25 mg per ml, 10 ml</u>	2,709	\$29,122	\$10.7500	C H 1%	
Cetirizine hydrochloride						
	<u>Oral liq 1 mg per ml</u>	6,777,929	\$119,292	\$0.0176	C H 1%	
	<u>Tab 10 mg</u>	18,758,180	\$298,255	\$0.0159	C H 1%	
Montelukast [current access]						
	Tab 10 mg	120,058	\$79,238	\$0.6600	C H 1%	PHARMAC would only award a tender for either current access or widened access. PHARMAC reserves the right to amend access. Units for period 1/8/12 to 1/5/13. Rebate currently exists.
	Tab 4 mg	16,043	\$10,588	\$0.6600	C H 1%	PHARMAC would only award a tender for either current access or widened access. PHARMAC reserves the right to amend access. Units for period 1/8/12 to 1/5/13. Rebate currently exists.
	Tab 5 mg	40,370	\$26,644	\$0.6600	C H 1%	PHARMAC would only award a tender for either current access or widened access. PHARMAC reserves the right to amend access. Units for period 1/8/12 to 1/5/13. Rebate currently exists.
Montelukast [widened access]						
	Tab 10 mg	120,058	\$79,238	\$0.6600	C H 1%	PHARMAC would only award a tender for either current access or widened access. PHARMAC reserves the right to amend access. Units for period 1/8/12 to 1/5/13. Rebate currently exists.

SCHEDULE ONE: PHARMACEUTICALS TO BE TENDERED (DRAFT)

Chemical Name

Line Item	Units	Cost	Unit Subsidy		DV Limit	Comments
Montelukast [widened access]						
Tab 4 mg	16,043	\$10,588	\$0.6600	C H	1%	PHARMAC would only award a tender for either current access or widened access. PHARMAC reserves the right to amend access. Units for period 1/8/12 to 1/5/13. Rebate currently exists.
Tab 5 mg	40,370	\$26,644	\$0.6600	C H	1%	PHARMAC would only award a tender for either current access or widened access. PHARMAC reserves the right to amend access. Units for period 1/8/12 to 1/5/13. Rebate currently exists.
Salmeterol						
Aerosol inhaler, 25 mcg per dose	12,351,960	\$2,723,607	\$0.2205	C H	1%	A rebate currently exists. Delisting and/or subsidy reduction and/or price protection until 1/07/2014
Powder for inhalation, 50 mcg per dose, breath activated	353,580	\$155,929	\$0.4410	C H	1%	A rebate currently exists. Delisting and/or subsidy reduction and/or price protection until 1/07/2014

Sensory Organs

Acetazolamide

Inj 500mg				C H	1%	Not currently listed in Section B of the Pharmaceutical Schedule
<u>Tab 250 mg</u>	430,192	\$73,262	\$0.1703	C H	1%	

Acetic acid with propylene glycol

Ear drops 2.3% with propylene glycol 2.8%				C H	1%	Not currently listed in Section B of the Pharmaceutical Schedule
---	--	--	--	-----	----	--

Acetylcholine chloride

Inj 20mg vial with diluent				C H	1%	Not currently listed in Section B of the Pharmaceutical Schedule
----------------------------	--	--	--	-----	----	--

Aciclovir

Eye oint 3%	26,925	\$224,555	\$8.3400	C H	1%	
-------------	--------	-----------	----------	-----	----	--

Apraclonidine

Eye drops 0.5%				C H	1%	Not currently listed in Section B of the Pharmaceutical Schedule
----------------	--	--	--	-----	----	--

Atropine sulphate

Eye drops 1%	92,055	\$106,538	\$1.1573	C H	1%	
Eye drops 1%, single dose				C H	1%	Not currently listed in Section B of the Pharmaceutical Schedule

Betaxolol hydrochloride

<u>Eye drops 0.25%</u>	32,655	\$77,066	\$2.3600	C H	1%	
<u>Eye drops 0.5%</u>	7,535	\$11,303	\$1.5000	C H	1%	

SCHEDULE ONE: PHARMACEUTICALS TO BE TENDERED (DRAFT)

Chemical Name

Line Item	Units	Cost	Unit Subsidy	DV Limit	Comments
Brimonidine tartrate					
<u>Eye Drops 0.15% - 0.2%</u>	148,460	\$191,513	\$1.2900	C H 1%	
Calcium chloride with magnesium chloride, potassium chloride, sodium acetate, sodium chloride and sodium citrate					
Eye drops 0.048% with magnesium chloride 0.03%, potassium chloride 0.075%, sodium acetate 0.39%, sodium chloride 0.64% and sodium acetate 0.17%, 15 ml				C H 1%	Not currently listed in Section B of the Pharmaceutical Schedule
Eye drops 0.048% with magnesium chloride 0.03%, potassium chloride 0.075%, sodium acetate 0.39%, sodium chloride 0.64% and sodium acetate 0.17%, 250 ml				C H 1%	Not currently listed in Section B of the Pharmaceutical Schedule
Eye drops 0.048% with magnesium chloride 0.03%, potassium chloride 0.075%, sodium acetate 0.39%, sodium chloride 0.64% and sodium acetate 0.17%, 500 ml				C H 1%	Not currently listed in Section B of the Pharmaceutical Schedule
Carbomer					
Ophthalmic gel 0.3%, single dose				C H 1%	Not currently listed in Section B of the Pharmaceutical Schedule
Ophthalmic gel 0.2%				C H 1%	Not currently listed in Section B of the Pharmaceutical Schedule
Carmellose sodium					
Eye drops 0.5%				C H 1%	Not currently listed in Section B of the Pharmaceutical Schedule
Eye drops 1%				C H 1%	Not currently listed in Section B of the Pharmaceutical Schedule
Chloramphenicol					
Ear drops 0.5%	25,405	\$11,178	\$0.4400	C H 1%	Single dose presentation would not be a DV Pharmaceutical
Eye drops 0.5%, single dose				H 1%	Not currently listed in Section B of the Pharmaceutical Schedule
Ciprofloxacin					
Eye Drops 0.3%	82,400	\$204,846	\$2.4860	C H 1%	
Cyclopentolate hydrochloride					
Eye drops 0.5%, single dose				H 1%	
Eye drops 1%	59,790	\$34,917	\$0.5840	C H 1%	
Eye drops 1%, single dose				H 1%	
Dexamethasone					
Eye drops 0.1 %	115,035	\$103,532	\$0.9000	C H 1%	
<u>Eye oint 0.1%</u>	13,746	\$23,015	\$1.6743	C H 1%	
Dexamethasone with framycetin and gramicidin					
Ear/eye drops 500 mcg with framycetin sulphate 5 mg and gramicidin 50 mcg per ml	629,304	\$353,984	\$0.5625 *	C H 1%	

SCHEDULE ONE: PHARMACEUTICALS TO BE TENDERED (DRAFT)

Chemical Name

Line Item	Units	Cost	Unit Subsidy		DV Limit	Comments
Dexamethasone with neomycin sulphate and polymyxin B sulphate						
<u>Eye drops 0.1% with neomycin sulphate 0.35% and polymyxin B sulphate 6,000 u per ml</u>	104,795	\$94,316	\$0.9000	C H	1%	
<u>Eye oint 0.1% with neomycin sulphate 0.35% and polymyxin B sulphate 6,000 u per g</u>	24,882	\$38,318	\$1.5400	C H	1%	
Dexamethasone with tobramycin						
Eye drops 0.1% with tobramycin 0.3%				C H	1%	Not currently listed in Section B of the Pharmaceutical Schedule
Diclofenac sodium						
<u>Eye drops 1 mg per ml, 5 ml</u>	69,055	\$190,592	\$2.7600	C H	1%	
Docusate sodium						
Ear drops 0.5%				C H	1%	Not currently listed in Section B of the Pharmaceutical Schedule
Dorzolamide hydrochloride						
Eye drops 2%	19,485	\$38,074	\$1.9540 *	C H	1%	
Dorzolamide hydrochloride with timolol maleate						
Eye drops 2% with timolol maleate 0.5%	359,235	\$1,113,629	\$3.1000	C H	1%	A rebate currently exists. Delisting and/or subsidy reduction and/or price protection 01/01/2014
Flumetasone pivalate with clioquinol						
Ear drops 0.02% with clioquinol 1%	277,315	\$164,910	\$0.5947	C H	1%	
Fluorescein sodium						
Eyedrops 2%, single dose				C H	1%	Not currently listed in Section B of the Pharmaceutical Schedule
Ophthalmic strips 1mg				C H	1%	Not currently listed in Section B of the Pharmaceutical Schedule
Fluorescein sodium with lignocaine hydrochloride						
Eye drops 0.25% with lignocaine hydrochloride 4% single dose				C H	1%	Not currently listed in Section B of the Pharmaceutical Schedule
Framycetin sulphate						
Ear/Eye drops 0.5%	38,472	\$19,861	\$0.5163 *	C H	1%	
Hydrocortisone with ciprofloxacin						
Ear drops 1% with ciprofloxacin 0.2%				C H	1%	Not currently listed in Section B of the Pharmaceutical Schedule. Any listing may be subject to a Special Authority restriction
Hypromellose						
Inj 2%, 1ml syringe				H	1%	
Inj 2%, 2ml syringe				H	1%	

SCHEDULE ONE: PHARMACEUTICALS TO BE TENDERED (DRAFT)

Chemical Name	Units	Cost	Unit Subsidy	DV Limit	Comments
Ketorolac trometamol					
Eye drops 0.5%				C H 1%	Not currently listed in Section B of the Pharmaceutical Schedule
Levocabastine					
Eye drops 0.5 mg per ml	149,072	\$324,604	\$2.1775 *	C H 1%	
Lissamine green					
Ophthalmic strips 1.5mg				C H 1%	Not currently listed in Section B of the Pharmaceutical Schedule
Lodoxamide					
<u>Eye drops 0.1%</u>	293,300	\$255,464	\$0.8710	C H 1%	
Naphazoline hydrochloride					
<u>Eye drops 0.1%</u>	122,460	\$33,881	\$0.2767	C H 1%	
Natamycin					
Eye drops 5%				C H 1%	Not currently listed in Section B of the Pharmaceutical Schedule
Oxybuprocaine hydrochloride					
Eye drops 0.4%, single dose				C H 1%	
Paraffin liquid with soft white paraffin					
<u>Eye oint with soft white paraffin</u>	143,716	\$149,054	\$1.0371	C H 1%	
Paraffin liquid with wool fat liquid					
Eye oint 3% with wool fat liq 3%	33,904	\$35,163	\$1.0371	C H 1%	
Phenylephrine hydrochloride					
Eye drops 10%, single dose				C H 1%	Not currently listed in Section B of the Pharmaceutical Schedule
Eye drops 2.5%, single dose				C H 1%	Not currently listed in Section B of the Pharmaceutical Schedule
Pilocarpine hydrochloride					
Eye drops 1%	19,590	\$5,564	\$0.2840	C H 1%	
Eye drops 2%	43,800	\$15,622	\$0.3567	C H 1%	
Eye drops 2% single dose	640	\$1,022	\$1.5975 *	C H 1%	
Eye drops 4%	35,235	\$18,769	\$0.5327	C H 1%	
Polyvinyl alcohol with povidone					
Eye drops 1.4% with povidone 0.6%, single dose				C H 1%	Not currently listed in Section B of the Pharmaceutical Schedule
Prednisolone sodium phosphate					
Eye drops 0.5%, single dose				C H 1%	Not currently listed in Section B of the Pharmaceutical Schedule. Any listing may be subject to a Special Authority restriction

SCHEDULE ONE: PHARMACEUTICALS TO BE TENDERED (DRAFT)

Chemical Name

Line Item	Units	Cost	Unit Subsidy	DV Limit	Comments
Propamidine isethionate					
Eye drops 0.1 %	1,330	\$395	\$0.2970 *	C H 1%	
Rose bengal sodium					
Ophthalmic strips 1%				C H 1%	Not currently listed in Section B of the Pharmaceutical Schedule
Sodium hyaluronate					
Inj 23 mg per ml, 0.6ml syringe				H 1%	
Sodium hyaluronate with chondroitin sulphate					
Inj 30mg with chondroitin sulphate 40mg per ml, 0.75ml syringe				H 1%	
<u>Inj 10 mg per ml, 0.5 ml; and inj 30 mg per ml with chondroitin sulphate 40 mg per ml, 0.55 ml</u>				H 1%	
Sulphacetamide sodium					
Eye drops 10%				C H 1%	Not currently listed in Section B of the Pharmaceutical Schedule
Tetracaine [amethocaine] hydrochloride					
Eye drops 0.5%, single dose				H 1%	
Eye drops 1%, single dose				H 1%	
Timolol maleate					
<u>Eye drops 0.25%</u>	125,050	\$52,021	\$0.4160	C H 1%	
<u>Eye drops 0.5%</u>	135,085	\$56,195	\$0.4160	C H 1%	
Tobramycin					
<u>Eye drops 0.3%</u>	3,570	\$8,197	\$2.2960	C H 1%	
<u>Eye oint 0.3%</u>	1,908	\$5,697	\$2.9857	C H 1%	
Tropicamide					
<u>Eye drops 0.5%</u>	765	\$365	\$0.4767	C H 1%	Single dose presentation would not be a DV Pharmaceutical
<u>Eye drops 1%</u>	4,080	\$2,356	\$0.5773	C H 1%	Single dose presentation would not be a DV Pharmaceutical